Hemolytic anemia caused by alectinib, an Anaplastic Lymphoma Kinase (ALK) inhibitor: A case report
Background: Anaplastic Lymphoma Kinase (ALK) inhibitors are tyrosine kinase inhibitors used as molecular-targeted therapy for non-small cell lung cancers (NSCLC) harbouring ALK translocations. Case description: This case report describes a 73-year-old female patient who was started on alectinib for...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-09-01
|
Series: | Current Problems in Cancer: Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2666621922000400 |